Health
New TB Vaccine in 100 Years Advances as Welcome, Gates Foundation Fund Trial
Welcome and the Bill & Melinda Gates Foundation have announced funding, to advance a tuberculosis (TB) vaccine candidate, M72/AS01E (M72), through a Phase III clinical trial.
If proven effective, M72 could potentially become the first new vaccine to help prevent pulmonary TB, a form of active TB, in more than 100 years.
Wellcome and the Bill & Melinda Gates Foundation made the announcement at a virtual news conference on Wednesday.
The event featured Trevor Mundel, President of Global Health at the Gates Foundation; Alexander Pym, Director of Infectious Diseases at Wellcome; and Nomathamsanga Majozi, Head of Public Engagement at the Africa Health Research Institute.
The only TB vaccine in use today, Bacille Calmette-Guérin (BCG), was first given to people in 1921.
It helps protect babies and young children against severe systemic forms of TB but offers limited protection against pulmonary TB among adolescents and adults.
TB is one of the world’s deadliest diseases, killing about 4,300 people per day, mostly those living in poverty.
In 2021, an estimated 10.6 million people fell ill with TB and 1.6 million died—about 4,300 people per day.
The disease primarily affects people in low and middle income countries, and those at highest risk are often living in poverty, with poor living and working conditions and undernutrition.
Up to a quarter of the world’s population is thought to have latent TB, a condition in which a person is infected with the bacterium that causes TB but does not have any symptoms and is at risk of progressing to active TB disease.
To support the M72 Phase III clinical trial, which will cost an estimated US$550 million, Wellcome is providing up to US$150 million and the Gates Foundation will fund the remainder, about US$400 million.
The vaccine, called M72, will be given from Year 2024 to 26,000 young adults in Africa and south-east Asia who have a latent infection with the bacteria that cause TB but no symptoms.
Commenting on the efficacy, Trevor Mundel, the Head of Global Health at the Bill & Melinda Gates Foundation, said that M72 had shown much promise in preventing TB in people with latent infections, but were not ill.
This, he said, was an important segment of the population to target.
However, “clear evidence about M72’s efficacy in preventing the emergence of active pulmonary tuberculosis will take several years to emerge from trial.
“Of course we’d be happy with 90 per cent efficacy but from our modelling, 50 per cent is good enough on the assumption that the durability is at least five years.
“Most of the vaccinologists who have looked at the data have said that is likely”.
He said the trial would probably last for four to six years.
Speaking on affordability, he said making the vaccine as affordable and as accessible as possible would be very important.
Julia Gillard, Chair of the Board of Governors at Wellcome, said: “TB remains one of the world’s deadliest infectious diseases.
“The development of an affordable, accessible vaccine for adults and adolescents would be game-changing in turning the tide against TB.
“Philanthropy can be a catalyst to drive progress, as shown by this funding of the M72 vaccine as a potential new tool in preventing escalating infectious diseases to protect those most affected.
“Sustainable progress against TB and wider disease threats will depend on global collaboration, financial backing, and political will.
“By working with communities and researchers in countries with a high burden of the disease, we can get one step closer to eliminating TB as a public health threat.”
Nomathamsanqa Majozi, Head of Public Engagement at Africa Health Research Institute, said: “Despite being curable, TB remains one of the leading causes of death in South Africa.
“In the area where I live and work, more than half of all people have had, or will have TB at some points in their lives.
“The consequences are devastating, both at a personal and a community level. M72 offers us new hope for a TB-free future.’’
Alexander Pym, the Director of Infectious Disease at Wellcome, said TB was one of the biggest health challenges in the world.
“Treatment is still four to six months long. Diagnostics can still not diagnose early enough to prevent transmission.
“Added to that is the threat of latent TB.”
He said the human immune response to TB was much more complex than to an acute viral infection and this made the process of developing a TB vaccine much longer.
“The challenge is big. We need new approaches and tools,” he said.
According to Pym, a TB vaccine will really be a game-changer; there is a need for TB innovation.
Bill Gates, Co-chair of the Bill & Melinda Gates Foundation, commented in a joint statement by the organisations.
“With TB cases and deaths on the rise, the need for new tools has never been more urgent.
“Greater investment in safe and effective TB vaccines, alongside a suite of new diagnostics and treatments could transform TB care for millions of people, saving lives and lowering the burden of this devastating and costly disease.”
World Health Organisation (WHO) Director-General, Dr Tedros Adhanom Ghebreyesus, commended the support by the Gates Foundation and Wellcome to develop a new TB vaccine.
“WHO welcomes the commitments from the Bill & Melinda Gates Foundation and Wellcome to take forward development of this vaccine candidate.
“WHO will keep supporting vaccine development and access more broadly through its TB Vaccine Accelerator Council.” (NAN)
Health
Expert Advocates For Elimination of Mother-to-Child Transmission of HIV Through HIV Self Testing.
From Attah Ede, Makurdi
Eliminating mother-to-child transmission of HIV in Nigeria is an achievable goal, but it requires innovative approaches that can address the unique barriers faced by women in underserved communities.
An expert on health related matters, Dr Godwin Emmanuel stated while interacting with newsmen as part of activities commemorating the just concluded World Aids Day in Makurdi, the Benue State capital.
Dr.
Emmanuel who is the Managing Partner/Impact Officer of MOZUK Future Solutions Limited, stated that the World AIDS Day have come and gone, yet Nigeria government must not fail to examine some of the gaps that must be urgently bridged as a nation.He explained that each year, thousands of children are born with HIV, largely due to inadequate access to testing and treatment during pregnancy, disclosing that the Joint United Nations Programme on HIV/AIDS (UNAIDS) estimates that Nigeria contributes about 22% of global paediatric HIV cases which indicates the urgent need for innovative approaches to curb MTCT.
“This brings me to a recent study in Lagos and Kano which demonstrated how HIV self-testing kits offer a practical, effective, and scalable solution to our MTCT challenges.
“The study interrogates an initiative seeking to integrate HIV Self-Test (HIVST) kits into TBA services as part of a broader strategy to eliminate MTCT.
“The intervention targeted underserved communities where healthcare access is limited, leveraging the trust and accessibility of TBAs to distribute self-testing kits and provide essential counselling”.
According to him, the study, led by Dr. Toriola Adebayo of Lagos State University Teaching Hospital and Dr. Usman Bashir of Aminu Kano Teaching Hospital, articulated the role of local expertise in advancing healthcare solutions tailored to community needs.
“In this intervention, 182 TBA clinics across three local government areas (LGAs) in Lagos and Kano States were equipped with HIVST kits. TBAs received extensive training on the administration of the tests, pre- and post-test counselling, and linkage to care for those who tested positive.
“Among the 1,982 pregnant women enrolled in the study, pre-intervention testing rates were markedly low, with just 60% in Lagos and 38% in Kano having ever been tested for HIV. After the introduction of HIVST, testing uptake surged, with all participants voluntarily using the kits during antenatal visits.
“The results were promising:
HIV Positivity Rate: An overall positivity rate of 0.8% was recorded, with slightly higher rates in Lagos (1.1%) compared to Kano (0.8%).
“First-Time Testers: Remarkably, 80% of those who tested positive were undergoing HIV testing for the first time.
Linkage to Care: All HIV-positive individuals were successfully linked to ART services, demonstrating the effectiveness of the TBA-led model in bridging gaps in healthcare access.
“The success of this initiative exemplifies how HIVST can become a cornerstone of affirmative action against paediatric HIV infections, which was also a critical focus of World AIDS Day observances.
“As evidenced by the success of the Lagos and Kano initiative, when confidentiality, stigma reduction, and leveraging trusted community figures like TBAs are prioritised, HIVST has the potential to transform PMTCT efforts across Nigeria.
“This is even more so with sustained investment, community buy-in, and political will. This can move us closer to a future where no child is born with HIV and every mother has the opportunity to live a healthy, fulfilling life”, Dr. Emmanuel alluded.
He further revealed that HIV self-testing kits offer a simple, private, and effective means of determining one’s HIV status, adding that the kits allow individuals to test themselves using a saliva sample or a small drop of blood, with results available in minutes.
Highlighting the importance, the health, said the convenience and confidentiality of this method are particularly appealing to those who might avoid traditional testing due to stigma or fear of disclosure.
He stated that the fear of being judged or ostracised often prevents pregnant women from seeking HIV testing, stressing that HIVST kits allow individuals to test in the comfort of their homes or a private setting, without fear of disclosure. This is particularly crucial for pregnant women, who may face compounded stigma if diagnosed with HIV.
“Increased Testing Uptake as demonstrated shown the intervention in Lagos and Kano demonstrates that when provided with confidential and convenient testing options, more women are willing to know their HIV status. Early diagnosis is key to initiating ART, which can reduce the risk of MTCT to less than 1%.
Health
NAFDAC Supports Herbal Medicine, says Must go Through Clinical Trials
Prof. Mojisola Adeyeye, the Director-General, National Agency for Food and Drug Administration and Control (NAFDAC), says she supports herbal medicine production in the country.
She said this on a Forum in Abuja.
She, however, explained that for NAFDAC to accommodate herbal medicine as part of its regulated products, such herbal preparation must go through clinical trials.
She disclosed that the major challenge to herbal medicine practitioners is how to secure resources to finance clinical trial for their products, which she said cost a lot of money because it is a major aspect in medicine.
She added that “I believe in natural medicine, I was brought up with it, like the Agbo that we were taking and it was working.
“Herbal medicine or natural medicine work, before I came back home from the United States, I started a research on natural medicine for the cure of sickle cell, my niece who is a sickler got on it and her episodes decreased by 70 to 80 per cent.”
She explained that the agency gives approval for natural medicines once proven it is not toxic, and they have been used and tested before.
“We approve them for two years and then they can renew if they do clinical trial because it is something we are not used to in Nigeria.
“China supports many of these herbal practitioners.”
The director-general also spoke about using fruits and vegetables as medicine to cure some illnesses, adding that some of these fruits contain antioxidants that prevent cancer. (NAN)
Health
NCDC Calms Fears over XEC COVID-19 Variant, Urges Continued Vigilance
The Nigeria Centre for Disease Control and Prevention (NCDC) has allayed public fears over the detection of the SARS-CoV-2 XEC subvariant globally.
The Director-General of the centre, Dr Jide Idris, did this in a public advisory issued on Saturday night in Abuja, made available to newsmen.
Idris reassured Nigerians that the variant, though identified in 29 countries, has not been detected in Nigeria.
He said that the XEC subvariant, a descendant of the Omicron JN.
1 lineage, was currently classified as a Variant Under Monitoring (VUM).According to him, this means that it is being closely observed for potential concerns but does not yet pose significant risk.
“The XEC sub-variant has been reported in Europe, Asia, North America, and Africa, with Botswana being the only African country to record cases so far.
“While the sub-variant exhibits higher transmissibility, there is no evidence of increased disease severity,” he said.
The NCDC boss said that Nigeria had been monitoring the JN.1 variant, classified as a Variant of Interest (VOI), which has been present in the country since January.
He assured Nigerians that the National COVID-19 Technical Working Group was conducting continuous surveillance and data analysis.
Additionally, he said that a dynamic risk assessment was being organised to strengthen the country’s preparedness and response capabilities.
He urged health facilities nationwide to ramp up COVID-19 testing and forward positive samples to accredited laboratories for genomic sequencing.
He encouraged the public to maintain vigilance and adhere to basic health protocols, including handwashing, mask usage in crowded spaces, and ensuring proper ventilation indoors.
He advised vulnerable groups, such as the elderly and those with underlying health conditions, to remain cautious.
“COVID-19 remains a significant risk, particularly for the elderly, individuals undergoing cancer treatment, organ transplant recipients, and those with suppressed immune systems.
“We urge Nigerians to get vaccinated and receive booster doses as recommended,” he said.
The director-general also called on state governments to enhance public health infrastructure, provide resources for improved surveillance and diagnostics, and promote public health education.
He reaffirmed the agency’s commitment to providing Nigerians with accurate and timely information on the evolving COVID-19 situation globally.
He urged citizens to avoid misinformation and rely on verified updates from its platforms.
“For assistance, the public is encouraged to contact the NCDC via its toll-free number 6232 or, WhatsApp: 07087110839, Twitter: @NCDCGov and Facebook: @NCDCgov,” he said.
Report says that the XEC variant of COVID-19 is a recombinant strain, meaning it results from the combination of genetic material from two or more existing variants of the SARS-CoV-2 virus.
Recombinant variants can emerge when different strains infect the same individual and exchange genetic material during replication.
This process may lead to new variants with unique properties, such as increased transmissibility, virulence, or resistance to immunity.
While thousands of mutations have been tracked globally, only a few variants are monitored for public health significance.
Nigeria’s NCDC and global health organizations like the WHO continue genomic surveillance to monitor and respond to emerging variants.(NAN)